Abstract:Background: In the Tumor Microenvironment (TME), hypoxia stands as a significant factor that modulates immune responses, especially those driven by T cells. As T cell-based therapies often fail to work in solid tumors, this study aims to investigate the effects of hypoxia on T cell topo-distribution in the TME, gene expression association with T cell states, and clinical responses in melanoma. Methods: To generate detailed information on tumor oxygenation and T cell accessibility, we utilized mathematical modeling of human melanoma tissue microarrays (TMAs) that incorporate oxygen supply from vessels, intratumoral diffusion, and cellular uptake. We created tumor maps and derived plots showing the fraction of CD4 and CD8 T cells against the distance to the nearest vessel and oxygen pressure. To assess their function and transcriptional changes caused by hypoxia, effector T cells were generated and cultured under hypoxia (0.5% oxygen) or normoxia (21% oxygen). The T cell hypoxia-transcriptional signature was compared against datasets from msigDB, iATLAS (clinical trials of melanoma patients treated with immune checkpoint inhibitors), ORIEN AVATAR (real-world melanoma patients treated with immune checkpoint inhibitors, ICIs), and a single-cell atlas of tumor-infiltrating lymphocytes (TILs). Results: We made three specific observations: 1) in melanoma T cells preferentially accumulated in oxygenated areas close to blood vessels (50-100 micrometers from the vasculature in the regions of high oxygen availability) but not in hypoxic areas far from blood vessels. 2) Our analysis confirmed that under hypoxia, T cell functions were significantly reduced compared to normoxic conditions and accompanied by a unique gene signature. Furthermore, this hypoxic gene signature was prevalent in resting and non-activated T cells. Notably and clinically relevant, the hypoxic T cell gene set was found to correlate with reduced Overall Survival (OS) and reduced progression-free survival (PFS) in melanoma patients, which was more pronounced in non-responder patients undergoing ICI therapy. 3) Finally, compared with a single-cell atlas of tumor-infiltrating T cells, our hypoxia signature aligned with a population of cells at a state termed stress response state (TSTR). Conclusion: Our study highlights the critical role of hypoxia in shaping T cell distribution and its correlation with clinical outcomes in melanoma. We revealed a preferential accumulation of T cells in oxygenated areas. Moreover, hypoxic T cells develop a distinct hypoxic gene signature prevalent in resting, non-activated T cells and TSTR that was also associated with poorer outcomes, particularly pronounced among non-responders to ICIs. ### Competing Interest Statement The authors have declared no competing interest.

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

Hypoxic Colorectal Cancer Cells Promote Metastasis of Normoxic Cancer Cells Depending on IL-8/p65 Signaling Pathway

Effector T Cells under Hypoxia Have an Altered Transcriptome Similar to Tumor-Stressed T Cells Found in Non-Responsive Melanoma Patients

Intratumor Hypoxia Promotes Immune Tolerance by Inducing Regulatory T Cells Via TGF-β1 in Gastric Cancer.

Hypoxia Enhances Immunosuppression by Inhibiting CD4+ Effector T Cell Function and Promoting Treg Activity

Regulatory T cell: a protection for tumour cells.

Differential induction of T-cell tolerance by tumour fibroblast subsets

Hypoxia Induced CCL28 Promotes Angiogenesis in Lung Adenocarcinoma by Targeting CCR3 on Endothelial Cells

A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

HIF1α Counteracts TGFβ1-Driven TSP1 Expression in Endothelial Cells to Stimulate Angiogenesis in the Hypoxic Tumor Microenvironment

Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development

Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies

Alleviating hypoxia to improve cancer immunotherapy

Targeting hypoxia signaling pathways in angiogenesis

Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

Cancer cells impair monocyte-mediated T cell stimulation to evade immunity

Regulatory T, B cells and inflammation: Do they play an important role in lung cancer?

Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression